Passage Bio Q3 2026 Earnings Date & Estimates

Passage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company developing genetic medicines for severe diseases of the central nervous system. The company focuses on conditions with significant unmet medical needs and uses adeno-associated virus (AAV) gene-delivery technologies to develop potential one-time treatments intended to address the underlying causes of disease.

Its research and development programs have included investigational therapies for rare neurological and neurodegenerative disorders, including GM1 gangliosidosis, Krabbe disease and frontotemporal dementia associated with progranulin gene mutations. Passage Bio’s programs are designed to deliver functional genetic material to targeted cells, with the goal of restoring or supporting production of proteins that are deficient or absent in affected patients.

Founded in 2018 and headquartered in Philadelphia, Passage Bio was established through a strategic relationship with the University of Pennsylvania’s Gene Therapy Program. The company’s development activities have centered on advancing therapies through clinical testing and regulatory evaluation, initially focusing on rare diseases affecting patients in the United States and other major biopharmaceutical markets.